Lexeo Therapeutics Inc [LXEO] stock is trading at $10.35, up 3.92%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The LXEO shares have gain 5.94% over the last week, with a monthly amount glided 13.86%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Lexeo Therapeutics Inc [NASDAQ: LXEO] stock has seen the most recent analyst activity on December 18, 2025, when Raymond James initiated its Strong Buy rating and assigned the stock a price target of $25. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on November 20, 2025, and set its price target to $19. On October 15, 2025, Guggenheim initiated with a Buy rating and assigned a price target of $30 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $20 on July 31, 2025. Robert W. Baird initiated its recommendation with a Outperform and recommended $28 as its price target on June 13, 2024. H.C. Wainwright started tracking with a Buy rating for this stock on June 06, 2024, and assigned it a price target of $22. In a note dated November 28, 2023, Stifel initiated an Buy rating and provided a target price of $20 on this stock.
Lexeo Therapeutics Inc [LXEO] stock has fluctuated between $1.45 and $10.56 over the past year. Currently, Wall Street analysts expect the stock to reach $20.57 within the next 12 months. Lexeo Therapeutics Inc [NASDAQ: LXEO] shares were valued at $10.35 at the most recent close of the market. An investor can expect a potential return of 98.74% based on the average LXEO price forecast.
Analyzing the LXEO fundamentals
Gross Profit Margin for this corporation currently stands at -0.28% with Operating Profit Margin at -63.49%, Pretax Profit Margin comes in at -58.73%, and Net Profit Margin reading is -58.73%. To continue investigating profitability, this company’s Return on Assets is posted at -0.65, Equity is -0.95 and Total Capital is -0.85. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.88 points at the first support level, and at 9.40 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.81, and for the 2nd resistance point, it is at 11.26.
Ratios To Look Out For
For context, Lexeo Therapeutics Inc’s Current Ratio is 7.40. Also, the Quick Ratio is 7.40, while the Cash Ratio stands at 1.12.
Transactions by insiders
Recent insider trading involved Townsend Richard Nolan, Chief Executive Officer, that happened on Nov 18 ’25 when 1127.0 shares were sold. Chief Medical Officer, Adler Eric completed a deal on Nov 18 ’25 to sell 615.0 shares. Meanwhile, Chief Development Officer See Tai Sandi sold 386.0 shares on Nov 18 ’25.
